GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

VISEN Pharmaceuticals 2561.HK · HKD

N/A · HKEX · 🇭🇰 Hong Kong

Compare

12.40

-6.63%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥160,729

FY2022FY2025

Net income

−CN¥246.9m

FY2022FY2025

Free cash flow

−CN¥450.2m

FY2022FY2025

Shareholders' equity

CN¥762.4m

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
RevenueCN¥160,729CN¥2.4m−CN¥1.4m−CN¥2.0m
Gross profitCN¥18,507CN¥2.4m−CN¥1.4m−CN¥2.0m
Research and developmentCN¥91.1mCN¥77.5mCN¥49.4mCN¥153.7m
Operating income−CN¥233.6m−CN¥149.1m−CN¥118.9m−CN¥306.8m
Net income−CN¥246.9m−CN¥156.0m−CN¥213.7m−CN¥247.4m
Diluted earnings per share-2.30-1.67-2.28-2.26

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assetsCN¥977.7mCN¥251.6mCN¥380.0mCN¥634.7m
Cash and short-term investmentsCN¥632.9mCN¥174.3mCN¥297.8mCN¥536.4m
Total liabilitiesCN¥215.3mCN¥45.0mCN¥45.3mCN¥75.9m
DebtCN¥177.1mCN¥2.0mCN¥3.1mCN¥5.1m
Shareholders' equityCN¥762.4mCN¥206.6mCN¥334.7mCN¥558.8m
Shares outstanding107m94m94m110m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations−CN¥447.6m−CN¥120.6m−CN¥232.3m−CN¥211.1m
Capital spending−CN¥2.6m−CN¥100,181−CN¥445,247−CN¥1.5m
Free cash flow−CN¥450.2m−CN¥120.7m−CN¥232.8m−CN¥212.6m

Financial ratios

Data as of 24 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin11.5%100.0%100.0%100.0%——
Operating margin-149208.3%-6556.8%14934.3%12547.8%——
Net margin-153589.7%-6562.5%14953.3%12574.7%——
Return on equity-32.4%-75.5%-63.8%-44.3%-57.4%-70.2%
Return on assets-25.2%-62.0%-56.2%-39.0%-52.3%-57.0%
Free cash flow yield-27.4%-9.9%-19.1%———
Revenue growth-94.2%-266.4%-27.4%———
Earnings growth35.5%-27.0%-13.6%-40.6%380.3%—
Current ratio4.47x4.26x7.22x8.15x11.76x5.86x
Debt to equity0.23x0.01x0.01x0.01x0.01x0.02x
Equity ratio78.0%82.1%88.1%88.0%91.1%81.1%
Interest coverage-224.22x-1130.94x-786.29x-465.83x-611.21x-265.63x
R&D as a share of sales56657.2%3259.7%-3456.6%-7813.1%——
Buybacks as a share of market value-14.6%0.0%————

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-8.7%——
Net income-0.1%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin94.4%116.6%——

Valuation history

At each fiscal year end

FY2025
Price to earnings-12.3

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.